Price Target Changed • Jun 08
Price target decreased by 9.0% to CN¥30.57 Down from CN¥33.59, the current price target is an average from 6 analysts. New target price is 37% above last closing price of CN¥22.28. Stock is down 51% over the past year. The company is forecast to post earnings per share of CN¥0.83 for next year compared to CN¥0.62 last year. New Risk • May 01
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 94% Cash payout ratio: 160% Dividend yield: 2.0% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 94% Cash payout ratio: 160% Minor Risk Profit margins are more than 30% lower than last year (6.1% net profit margin). Announcement • Apr 30
Guangdong Marubi Biotechnology Co., Ltd., Annual General Meeting, May 25, 2026 Guangdong Marubi Biotechnology Co., Ltd., Annual General Meeting, May 25, 2026, at 14:30 China Standard Time. Location: 11F, No. 69, Xingang East Road, Haizhu District, Guangzhou, Guangdong China Price Target Changed • Apr 07
Price target decreased by 7.3% to CN¥35.95 Down from CN¥38.78, the current price target is an average from 7 analysts. New target price is 48% above last closing price of CN¥24.31. Stock is down 33% over the past year. The company is forecast to post earnings per share of CN¥0.93 for next year compared to CN¥0.62 last year. New Risk • Apr 05
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.1% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (438% cash payout ratio). Profit margins are more than 30% lower than last year (7.1% net profit margin). Announcement • Mar 30
Guangdong Marubi Biotechnology Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Buy Or Sell Opportunity • Jan 09
Now 20% overvalued Over the last 90 days, the stock has fallen 11% to CN¥34.46. The fair value is estimated to be CN¥28.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 70% in the next 2 years. Announcement • Dec 26
Guangdong Marubi Biotechnology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 01, 2026 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 01, 2026 Reported Earnings • Oct 31
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥0.15 (down from CN¥0.16 in 3Q 2024). Revenue: CN¥681.2m (up 14% from 3Q 2024). Net income: CN¥58.2m (down 6.6% from 3Q 2024). Profit margin: 8.5% (down from 10% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 4.9%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Guangdong Marubi Biotechnology Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 New Risk • Aug 25
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 115% Cash payout ratio: 318% Dividend yield: 1.8% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 25
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: EPS: CN¥0.12 (down from CN¥0.16 in 2Q 2024). Revenue: CN¥922.5m (up 34% from 2Q 2024). Net income: CN¥50.7m (down 23% from 2Q 2024). Profit margin: 5.5% (down from 9.5% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 58%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Jun 30
Guangdong Marubi Biotechnology Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 New Risk • May 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.8% average weekly change). New Risk • May 05
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows. Price Target Changed • May 01
Price target increased by 13% to CN¥37.98 Up from CN¥33.73, the current price target is an average from 9 analysts. New target price is 20% below last closing price of CN¥47.40. Stock is up 56% over the past year. The company is forecast to post earnings per share of CN¥0.89 for next year compared to CN¥0.65 last year. Announcement • Apr 30
Guangdong Marubi Biotechnology Co., Ltd., Annual General Meeting, May 22, 2025 Guangdong Marubi Biotechnology Co., Ltd., Annual General Meeting, May 22, 2025, at 14:30 China Standard Time. Valuation Update With 7 Day Price Move • Apr 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥47.40, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 21x in the Personal Products industry in China. Total returns to shareholders of 138% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥51.57 per share. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥40.30, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 22x in the Personal Products industry in China. Total returns to shareholders of 82% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥39.98 per share. Announcement • Mar 28
Guangdong Marubi Biotechnology Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 Buy Or Sell Opportunity • Jan 22
Now 20% undervalued Over the last 90 days, the stock has risen 8.4% to CN¥32.35. The fair value is estimated to be CN¥40.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 57% in 2 years. Earnings are forecast to grow by 68% in the next 2 years. Buy Or Sell Opportunity • Jan 03
Now 23% undervalued Over the last 90 days, the stock has risen 8.7% to CN¥31.32. The fair value is estimated to be CN¥40.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 57% in 2 years. Earnings are forecast to grow by 68% in the next 2 years. Announcement • Dec 27
Guangdong Marubi Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Price Target Changed • Nov 04
Price target increased by 7.1% to CN¥30.43 Up from CN¥28.42, the current price target is an average from 8 analysts. New target price is approximately in line with last closing price of CN¥29.66. Stock is up 11% over the past year. The company is forecast to post earnings per share of CN¥0.92 for next year compared to CN¥0.65 last year. Reported Earnings • Oct 26
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: CN¥0.16 (up from CN¥0.10 in 3Q 2023). Revenue: CN¥600.0m (up 26% from 3Q 2023). Net income: CN¥62.3m (up 44% from 3Q 2023). Profit margin: 10% (up from 9.0% in 3Q 2023). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Guangdong Marubi Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥26.14, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Personal Products industry in China. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥31.54 per share. Major Estimate Revision • Sep 03
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥2.97b to CN¥2.92b. EPS estimate also fell from CN¥1.04 per share to CN¥0.925 per share. Net income forecast to grow 36% next year vs 25% growth forecast for Personal Products industry in China. Consensus price target down from CN¥33.43 to CN¥28.63. Share price rose 2.9% to CN¥21.18 over the past week. Price Target Changed • Aug 28
Price target decreased by 14% to CN¥28.63 Down from CN¥33.43, the current price target is an average from 7 analysts. New target price is 38% above last closing price of CN¥20.76. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.92 for next year compared to CN¥0.65 last year. Reported Earnings • Aug 24
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: CN¥0.16 (up from CN¥0.13 in 2Q 2023). Revenue: CN¥690.9m (up 19% from 2Q 2023). Net income: CN¥65.9m (up 27% from 2Q 2023). Profit margin: 9.5% (in line with 2Q 2023). Revenue missed analyst estimates by 8.3%. Earnings per share (EPS) also missed analyst estimates by 31%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings. Announcement • Jun 28
Guangdong Marubi Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024 New Risk • May 18
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 32% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Price Target Changed • May 04
Price target increased by 9.2% to CN¥32.56 Up from CN¥29.82, the current price target is an average from 7 analysts. New target price is 7.3% above last closing price of CN¥30.33. Stock is down 22% over the past year. The company is forecast to post earnings per share of CN¥0.72 for next year compared to CN¥0.43 last year. Announcement • Apr 29
Guangdong Marubi Biotechnology Co., Ltd., Annual General Meeting, May 17, 2024 Guangdong Marubi Biotechnology Co., Ltd., Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China Price Target Changed • Apr 28
Price target increased by 7.2% to CN¥30.93 Up from CN¥28.86, the current price target is an average from 7 analysts. New target price is 9.3% above last closing price of CN¥28.29. Stock is down 22% over the past year. The company is forecast to post earnings per share of CN¥0.72 for next year compared to CN¥0.43 last year. Announcement • Mar 29
Guangdong Marubi Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Announcement • Dec 29
Guangdong Marubi Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2023 results: EPS: CN¥0.10 (up from CN¥0.007 in 3Q 2022). Revenue: CN¥477.0m (up 46% from 3Q 2022). Net income: CN¥43.1m (up CN¥40.2m from 3Q 2022). Profit margin: 9.0% (up from 0.9% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 27%. Earnings per share (EPS) missed analyst estimates by 27%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Price Target Changed • Sep 02
Price target decreased by 9.3% to CN¥31.49 Down from CN¥34.70, the current price target is an average from 8 analysts. New target price is 16% above last closing price of CN¥27.05. Stock is up 3.8% over the past year. The company is forecast to post earnings per share of CN¥0.74 for next year compared to CN¥0.43 last year. Reported Earnings • Aug 26
Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.13 (in line with 2Q 2022). Revenue: CN¥582.7m (up 34% from 2Q 2022). Net income: CN¥52.0m (flat on 2Q 2022). Profit margin: 8.9% (down from 12% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. Price Target Changed • Aug 05
Price target increased by 11% to CN¥34.70 Up from CN¥31.23, the current price target is an average from 8 analysts. New target price is 17% above last closing price of CN¥29.55. Stock is up 21% over the past year. The company is forecast to post earnings per share of CN¥0.75 for next year compared to CN¥0.43 last year. Price Target Changed • May 07
Price target increased by 7.4% to CN¥30.98 Up from CN¥28.85, the current price target is an average from 9 analysts. New target price is 21% below last closing price of CN¥39.08. Stock is up 83% over the past year. The company is forecast to post earnings per share of CN¥0.84 for next year compared to CN¥0.43 last year. Reported Earnings • May 02
First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.16 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.20 (up from CN¥0.16 in 1Q 2022). Revenue: CN¥476.7m (up 25% from 1Q 2022). Net income: CN¥78.7m (up 20% from 1Q 2022). Profit margin: 17% (in line with 1Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥38.55, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 27x in the Personal Products industry in China. Total loss to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥31.04 per share. Price Target Changed • Dec 09
Price target increased to CN¥28.13 Up from CN¥26.26, the current price target is an average from 9 analysts. New target price is 23% below last closing price of CN¥36.63. Stock is up 14% over the past year. The company is forecast to post earnings per share of CN¥0.61 for next year compared to CN¥0.62 last year. Price Target Changed • Nov 23
Price target increased to CN¥27.55 Up from CN¥24.95, the current price target is an average from 9 analysts. New target price is 27% below last closing price of CN¥37.50. Stock is up 22% over the past year. The company is forecast to post earnings per share of CN¥0.63 for next year compared to CN¥0.62 last year. Board Change • Nov 16
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. 1 highly experienced director. No independent directors (4 non-independent directors). Chairman & CEO Huaiqing Sun is the most experienced director on the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥33.20, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 23x in the Personal Products industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥36.31 per share. Buying Opportunity • Nov 02
Now 21% undervalued Over the last 90 days, the stock is up 17%. The fair value is estimated to be CN¥36.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 37%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 15% per annum over the same time period. Reported Earnings • Oct 29
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: CN¥0.007 (up from CN¥0.11 loss in 3Q 2021). Revenue: CN¥326.5m (up 24% from 3Q 2021). Net income: CN¥2.94m (up CN¥50.1m from 3Q 2021). Profit margin: 0.9% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 8.5%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥26.50, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 22x in the Personal Products industry in China. Total loss to shareholders of 54% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥15.72 per share. Reported Earnings • Aug 29
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2022 results: EPS: CN¥0.13 (down from CN¥0.22 in 2Q 2021). Revenue: CN¥434.5m (down 7.5% from 2Q 2021). Net income: CN¥51.6m (down 42% from 2Q 2021). Profit margin: 12% (down from 19% in 2Q 2021). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 43%. Over the next year, revenue is forecast to grow 20%, compared to a 28% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥27.54, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 26x in the Personal Products industry in China. Total loss to shareholders of 47% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥14.39 per share. Major Estimate Revision • May 10
Consensus EPS estimates fall by 26% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥2.09b to CN¥1.92b. EPS estimate also fell from CN¥0.95 per share to CN¥0.71 per share. Net income forecast to grow 48% next year vs 36% growth forecast for Personal Products industry in China. Consensus price target down from CN¥28.80 to CN¥25.55. Share price rose 5.0% to CN¥21.81 over the past week. Reported Earnings • May 02
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: EPS: CN¥0.16 (down from CN¥0.25 in 1Q 2021). Revenue: CN¥382.7m (down 5.3% from 1Q 2021). Net income: CN¥65.5m (down 35% from 1Q 2021). Profit margin: 17% (down from 25% in 1Q 2021). The decrease in margin was primarily driven by lower revenue. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 24%, compared to a 28% growth forecast for the industry in China. Price Target Changed • Apr 27
Price target decreased to CN¥30.36 Down from CN¥44.52, the current price target is an average from 14 analysts. New target price is 49% above last closing price of CN¥20.31. Stock is down 64% over the past year. The company is forecast to post earnings per share of CN¥0.73 for next year compared to CN¥1.16 last year. Price Target Changed • Nov 04
Price target decreased to CN¥42.65 Down from CN¥47.05, the current price target is an average from 14 analysts. New target price is 43% above last closing price of CN¥29.90. Stock is down 53% over the past year. The company is forecast to post earnings per share of CN¥1.10 for next year compared to CN¥1.16 last year. Reported Earnings • Nov 01
Third quarter 2021 earnings released: CN¥0.11 loss per share (vs CN¥0.17 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: CN¥263.9m (down 23% from 3Q 2020). Net loss: CN¥47.1m (down 168% from profit in 3Q 2020). Valuation Update With 7 Day Price Move • Sep 21
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥38.85, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 27x in the Personal Products industry in China. Total loss to shareholders of 40% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥48.15 per share. Price Target Changed • Aug 30
Price target decreased to CN¥58.22 Down from CN¥62.97, the current price target is an average from 12 analysts. New target price is 73% above last closing price of CN¥33.63. Stock is down 56% over the past year. Reported Earnings • Aug 29
Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.37 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥469.7m (up 11% from 2Q 2020). Net income: CN¥89.0m (down 40% from 2Q 2020). Profit margin: 19% (down from 35% in 2Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Apr 25
Full year 2020 earnings released: EPS CN¥1.16 (vs CN¥1.37 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.74b (down 3.1% from FY 2019). Net income: CN¥464.4m (down 9.8% from FY 2019). Profit margin: 27% (down from 29% in FY 2019). Price Target Changed • Apr 01
Price target decreased to CN¥73.43 Down from CN¥80.60, the current price target is an average from 13 analysts. New target price is 35% above last closing price of CN¥54.25. Stock is down 21% over the past year. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥56.90, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 36x in the Personal Products industry in China. Total loss to shareholders of 11% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥32.74 per share. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥56.33, the stock is trading at a trailing P/E ratio of 45.6x, up from the previous P/E ratio of 37x. This compares to an average P/E of 41x in the Personal Products industry in China. Total return to shareholders over the past year is a loss of 16%. Is New 90 Day High Low • Feb 03
New 90-day low: CN¥45.71 The company is down 29% from its price of CN¥64.04 on 05 November 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥34.48 per share. Is New 90 Day High Low • Jan 13
New 90-day low: CN¥50.83 The company is down 26% from its price of CN¥68.30 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥42.30 per share. Is New 90 Day High Low • Dec 23
New 90-day low: CN¥54.69 The company is down 14% from its price of CN¥63.36 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥42.95 per share. Announcement • Dec 14
Guangdong Marubi Biotechnology Co., Ltd.(XSSC:603983) dropped from FTSE All-World Index (USD) Guangdong Marubi Biotechnology Co., Ltd.(XSSC:603983) dropped from FTSE All-World Index (USD) Price Target Changed • Dec 09
Price target lowered to CN¥84.17 Down from CN¥92.34, the current price target is an average from 13 analysts. The new target price is 47% above the current share price of CN¥57.18. As of last close, the stock is down 7.2% over the past year. Is New 90 Day High Low • Nov 17
New 90-day low: CN¥60.10 The company is down 20% from its price of CN¥74.78 on 19 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥37.83 per share. Is New 90 Day High Low • Oct 30
New 90-day low: CN¥61.97 The company is down 19% from its price of CN¥76.96 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥41.89 per share. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥493.8m, down 8.3% from the prior year. Total revenue was CN¥1.73b over the last 12 months, largely unchanged from the prior year. Is New 90 Day High Low • Sep 24
New 90-day low: CN¥63.36 The company is down 24% from its price of CN¥83.35 on 24 June 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥43.77 per share. Announcement • Jul 10
Guangdong Marubi Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020 Guangdong Marubi Biotechnology Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020